AU2001259295A1 - Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane - Google Patents

Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane

Info

Publication number
AU2001259295A1
AU2001259295A1 AU2001259295A AU5929501A AU2001259295A1 AU 2001259295 A1 AU2001259295 A1 AU 2001259295A1 AU 2001259295 A AU2001259295 A AU 2001259295A AU 5929501 A AU5929501 A AU 5929501A AU 2001259295 A1 AU2001259295 A1 AU 2001259295A1
Authority
AU
Australia
Prior art keywords
systemiccirculation
composition
bioactive compounds
rapid delivery
nasal membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001259295A
Inventor
Robert S. Davidson
Charles Hensley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zengen Inc
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of AU2001259295A1 publication Critical patent/AU2001259295A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU2001259295A 2000-04-28 2001-04-30 Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane Abandoned AU2001259295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20028600P 2000-04-28 2000-04-28
US60200286 2000-04-28
PCT/US2001/013973 WO2001082902A1 (en) 2000-04-28 2001-04-30 Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane

Publications (1)

Publication Number Publication Date
AU2001259295A1 true AU2001259295A1 (en) 2001-11-12

Family

ID=22741068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001259295A Abandoned AU2001259295A1 (en) 2000-04-28 2001-04-30 Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane

Country Status (2)

Country Link
AU (1) AU2001259295A1 (en)
WO (1) WO2001082902A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2455170A1 (en) 2000-07-31 2002-02-07 Ottawa Heart Institute Research Corporation Charged phospholipid compositions and methods for their use
IL158139A0 (en) * 2003-09-25 2004-09-27 Enzymotec Ltd Stabilized formulations of phosphatidyl serine
US8052992B2 (en) 2003-10-22 2011-11-08 Enzymotec Ltd. Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions
US20050130937A1 (en) 2003-10-22 2005-06-16 Enzymotec Ltd. Lipids containing omega-3 and omega-6 fatty acids
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
US20060275356A1 (en) * 2005-05-25 2006-12-07 Burgess James W Pharmaceutical compositions for treating or preventing coronary artery disease
CN108498790A (en) * 2018-07-04 2018-09-07 烟台凯多海洋生物研究院有限公司 It is to wrap up protectant SOD Compositional types cancer rehabilitation agent with chitosan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413804A (en) * 1991-04-23 1995-05-09 Cacique, Inc. Process for making whey-derived fat substitute product and products thereof
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US5885974A (en) * 1994-12-06 1999-03-23 Michael M. Danielov Therapeutic methods utilizing naturally derived bio-active complexes and delivery systems therefor

Also Published As

Publication number Publication date
WO2001082902A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
AU2003266159A1 (en) System and method for delivering a composition to the nasal membrane
HK1071704A1 (en) Composition having gelling properties for the prolonged delivery of bioactive substances []
AU2002222118A1 (en) Pharmaceutical compositions for inhalation
HUP0302792A3 (en) Cyclopropyl-fused pyrrolidine-based onhibitors of dipeptidyl peptidase iv and method for their preparation and pharmaceutical compositions containing the compounds
AU2001273034A1 (en) Composition for delivery of hematopoietic growth factor
AU4949800A (en) 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2002258221A1 (en) Medicinal composition
AU2001288395A1 (en) Method for enhanced delivery of oxybutynin and compositions thereof
AU2002231095A1 (en) Method and composition for the treatment of diabetic neuropathy
AU2003278806A1 (en) Composition and method for moisturizing nasal tissue
AU2001290239A1 (en) Medicinal composition
AU2001259295A1 (en) Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
AU2002256304A1 (en) Compositions for delivery of compounds to cells and methods of use
HUP0204448A3 (en) Trnasdermal therapeutic system for the delivery of lerisetron
AU2001292865A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
AU2001232017A1 (en) Pharmaceutical composition for pulmonary delivery
AU2001261732A1 (en) Composition for delivery of compounds to cells
AU2002215114A1 (en) Pharmaceutical compositions for inhalation
AU2002214976A1 (en) Process for the preparation of benzotriazoles
AU1224300A (en) Composition for the transdermal delivery of lerisetron
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU1866700A (en) Formulation for delivery of particulate material to mucosal membranes
AU2001280299A1 (en) Improvements in and relating to methods and apparatus for the application of honey to wounds